280 related articles for article (PubMed ID: 25986626)
1. Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer's Disease.
Ajith TA; Padmajanair G
Curr Aging Sci; 2015; 8(3):235-40. PubMed ID: 25986626
[TBL] [Abstract][Full Text] [Related]
2. Small molecules as therapeutic drugs for Alzheimer's disease.
Oliver DMA; Reddy PH
Mol Cell Neurosci; 2019 Apr; 96():47-62. PubMed ID: 30877034
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
Beal MF
J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
5. Antioxidant pathways in Alzheimer's disease: possibilities of intervention.
Viña J; Lloret A; Giraldo E; Badia MC; Alonso MD
Curr Pharm Des; 2011 Dec; 17(35):3861-4. PubMed ID: 21933145
[TBL] [Abstract][Full Text] [Related]
6. A cAMP analog attenuates beta-amyloid (1-42)-induced mitochondrial dysfunction and spatial learning and memory deficits.
Aghsami M; Sharifzadeh M; Sepand MR; Yazdankhah M; Seyednejad SA; Pourahmad J
Brain Res Bull; 2018 Jun; 140():34-42. PubMed ID: 29605485
[TBL] [Abstract][Full Text] [Related]
7. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction: different routes to Alzheimer's disease therapy.
Picone P; Nuzzo D; Caruana L; Scafidi V; Di Carlo M
Oxid Med Cell Longev; 2014; 2014():780179. PubMed ID: 25221640
[TBL] [Abstract][Full Text] [Related]
9. Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis.
Kawada H; Blessing K; Kiyota T; Woolman T; Winchester L; Kador PF
J Alzheimers Dis; 2015; 44(1):297-307. PubMed ID: 25227315
[TBL] [Abstract][Full Text] [Related]
10. Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease.
Yang P; Sheng D; Guo Q; Wang P; Xu S; Qian K; Li Y; Cheng Y; Wang L; Lu W; Zhang Q
Biomaterials; 2020 Apr; 238():119844. PubMed ID: 32062148
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer's disease patients.
Birnbaum JH; Wanner D; Gietl AF; Saake A; Kündig TM; Hock C; Nitsch RM; Tackenberg C
Stem Cell Res; 2018 Mar; 27():121-130. PubMed ID: 29414602
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression.
Manczak M; Anekonda TS; Henson E; Park BS; Quinn J; Reddy PH
Hum Mol Genet; 2006 May; 15(9):1437-49. PubMed ID: 16551656
[TBL] [Abstract][Full Text] [Related]
13. Effect of Coenzyme Q10 supplementation on mitochondrial electron transport chain activity and mitochondrial oxidative stress in Coenzyme Q10 deficient human neuronal cells.
Duberley KE; Heales SJ; Abramov AY; Chalasani A; Land JM; Rahman S; Hargreaves IP
Int J Biochem Cell Biol; 2014 May; 50():60-3. PubMed ID: 24534273
[TBL] [Abstract][Full Text] [Related]
14. Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants.
Di Domenico F; Barone E; Perluigi M; Butterfield DA
Expert Rev Neurother; 2015 Jan; 15(1):19-40. PubMed ID: 25243342
[TBL] [Abstract][Full Text] [Related]
15. beta-Amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease.
Arias C; Montiel T; Quiroz-Báez R; Massieu L
Exp Neurol; 2002 Jul; 176(1):163-74. PubMed ID: 12093093
[TBL] [Abstract][Full Text] [Related]
16. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
17. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease.
Ajith TA
Clin Exp Pharmacol Physiol; 2018 May; 45(5):413-421. PubMed ID: 29112771
[TBL] [Abstract][Full Text] [Related]
18. The key role of mitochondria in Alzheimer's disease.
Moreira PI; Cardoso SM; Santos MS; Oliveira CR
J Alzheimers Dis; 2006 Jul; 9(2):101-10. PubMed ID: 16873957
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Dysfunction in Neocortex and Hippocampus of Olfactory Bulbectomized Mice, a Model of Alzheimer's Disease.
Avetisyan AV; Samokhin AN; Alexandrova IY; Zinovkin RA; Simonyan RA; Bobkova NV
Biochemistry (Mosc); 2016 Jun; 81(6):615-23. PubMed ID: 27301290
[TBL] [Abstract][Full Text] [Related]
20. POTENTIAL APPROACHES FOR REDUCING AMYLOID β PRODUCTION.
Zheng C; Lan Y; Zhang J; Zhang L; Wu J; Guo S
Acta Pol Pharm; 2016 Jul; 73(4):835-842. PubMed ID: 29648708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
